Logistic regression analysis on combined genotypes
. | Genotype . | . | No. of samples . | . | . | . | ||
|---|---|---|---|---|---|---|---|---|
| Patient group . | RAD51-135G/C . | HLX1-C/T (3′ UTR) . | Control . | AML . | OR (95% CI) . | P . | ||
| De novo AML | ||||||||
| 1 | WT | WT | 106 | 80 | 1.0* | — | ||
| 2 | WT | V | 30 | 22 | 0.90 (0.47-1.71) | .75 | ||
| 3 | V | WT | 15 | 16 | 1.42 (0.66-3.06) | .37 | ||
| 4 | V | V | 4 | 5 | 1.80 (0.47-6.97) | .39 | ||
| t-AML | ||||||||
| 1 | WT | WT | 106 | 17 | 1.0* | — | ||
| 2 | WT | V | 30 | 11 | 2.31 (0.96-5.57) | .06 | ||
| 3 | V | WT | 15 | 3 | 1.26 (0.32-4.87) | .74 | ||
| 4 | V | V | 4 | 5 | 9.50 (2.22-40.64) | .002 | ||
. | Genotype . | . | No. of samples . | . | . | . | ||
|---|---|---|---|---|---|---|---|---|
| Patient group . | RAD51-135G/C . | HLX1-C/T (3′ UTR) . | Control . | AML . | OR (95% CI) . | P . | ||
| De novo AML | ||||||||
| 1 | WT | WT | 106 | 80 | 1.0* | — | ||
| 2 | WT | V | 30 | 22 | 0.90 (0.47-1.71) | .75 | ||
| 3 | V | WT | 15 | 16 | 1.42 (0.66-3.06) | .37 | ||
| 4 | V | V | 4 | 5 | 1.80 (0.47-6.97) | .39 | ||
| t-AML | ||||||||
| 1 | WT | WT | 106 | 17 | 1.0* | — | ||
| 2 | WT | V | 30 | 11 | 2.31 (0.96-5.57) | .06 | ||
| 3 | V | WT | 15 | 3 | 1.26 (0.32-4.87) | .74 | ||
| 4 | V | V | 4 | 5 | 9.50 (2.22-40.64) | .002 | ||
Variant (V) genotype includes all heterozygous and variant homozygous genotypes. Wild-type (WT) genotype comprises the homozygous genotype for the most common and frequent genotype. The AML patient groups have been compared with the control group and adjusted for age.
Used as reference group.